A perspective on the cost-benefit of drug therapy

J Lyle Bootman, William F. Mcghan

Research output: Contribution to journalArticle

Abstract

Cost-benefit analysis is an important tool in assessing the impact of drugs on society. The purpose of this paper is to assess the cost-benefit of drugs to society and specifically to consider whether it is cost-beneficial for insurance and entitlement programs to include drug coverage in their health benefits package. Although prescription and over-the-counter drugs represent only 7.5 percent of total health care costs, drugs have been responsible for dramatic improvements in the health status of the public in this country. If we had the same diseases and mortality rates in recent years that we had at the turn of the century, we would have foregone billions of dollars annually due to loss of life and loss of work days. Our calculations demonstrate that even if drugs accounted for only 10 percent of the improvement in mortality and morbidity figures, the benefits of drugs definitely exceed the annual expenditures (costs) for drugs. The evidence indicates that it is very cost-beneficial for employers, insurance carriers, and third-party payors to include drug coverage in their insurance package. Drugs are an important factor in reducing the costs in areas such as labor absenteeism as well as the more costly interventions such as hospitalization and surgery.

Original languageEnglish (US)
Pages (from-to)53-69
Number of pages17
JournalClinical Research and Regulatory Affairs
Volume3
Issue number1
DOIs
StatePublished - 1985

Fingerprint

Cost-Benefit Analysis
Drug Therapy
Pharmaceutical Preparations
Insurance
Costs and Cost Analysis
Nonprescription Drugs
Health Insurance Reimbursement
Absenteeism
Insurance Carriers
Drug Costs
Mortality
Insurance Benefits
Health Expenditures
Health Care Costs
Health Status
Prescriptions
Hospitalization
Morbidity

ASJC Scopus subject areas

  • Pharmaceutical Science
  • Pharmacology
  • Pharmacology (medical)

Cite this

A perspective on the cost-benefit of drug therapy. / Bootman, J Lyle; Mcghan, William F.

In: Clinical Research and Regulatory Affairs, Vol. 3, No. 1, 1985, p. 53-69.

Research output: Contribution to journalArticle

@article{3e652ef5e707468d9230cfa38816efa5,
title = "A perspective on the cost-benefit of drug therapy",
abstract = "Cost-benefit analysis is an important tool in assessing the impact of drugs on society. The purpose of this paper is to assess the cost-benefit of drugs to society and specifically to consider whether it is cost-beneficial for insurance and entitlement programs to include drug coverage in their health benefits package. Although prescription and over-the-counter drugs represent only 7.5 percent of total health care costs, drugs have been responsible for dramatic improvements in the health status of the public in this country. If we had the same diseases and mortality rates in recent years that we had at the turn of the century, we would have foregone billions of dollars annually due to loss of life and loss of work days. Our calculations demonstrate that even if drugs accounted for only 10 percent of the improvement in mortality and morbidity figures, the benefits of drugs definitely exceed the annual expenditures (costs) for drugs. The evidence indicates that it is very cost-beneficial for employers, insurance carriers, and third-party payors to include drug coverage in their insurance package. Drugs are an important factor in reducing the costs in areas such as labor absenteeism as well as the more costly interventions such as hospitalization and surgery.",
author = "Bootman, {J Lyle} and Mcghan, {William F.}",
year = "1985",
doi = "10.3109/10601338509051049",
language = "English (US)",
volume = "3",
pages = "53--69",
journal = "Clinical Research Practices and Drug Regulatory Affairs",
issn = "1060-1333",
publisher = "Informa Healthcare",
number = "1",

}

TY - JOUR

T1 - A perspective on the cost-benefit of drug therapy

AU - Bootman, J Lyle

AU - Mcghan, William F.

PY - 1985

Y1 - 1985

N2 - Cost-benefit analysis is an important tool in assessing the impact of drugs on society. The purpose of this paper is to assess the cost-benefit of drugs to society and specifically to consider whether it is cost-beneficial for insurance and entitlement programs to include drug coverage in their health benefits package. Although prescription and over-the-counter drugs represent only 7.5 percent of total health care costs, drugs have been responsible for dramatic improvements in the health status of the public in this country. If we had the same diseases and mortality rates in recent years that we had at the turn of the century, we would have foregone billions of dollars annually due to loss of life and loss of work days. Our calculations demonstrate that even if drugs accounted for only 10 percent of the improvement in mortality and morbidity figures, the benefits of drugs definitely exceed the annual expenditures (costs) for drugs. The evidence indicates that it is very cost-beneficial for employers, insurance carriers, and third-party payors to include drug coverage in their insurance package. Drugs are an important factor in reducing the costs in areas such as labor absenteeism as well as the more costly interventions such as hospitalization and surgery.

AB - Cost-benefit analysis is an important tool in assessing the impact of drugs on society. The purpose of this paper is to assess the cost-benefit of drugs to society and specifically to consider whether it is cost-beneficial for insurance and entitlement programs to include drug coverage in their health benefits package. Although prescription and over-the-counter drugs represent only 7.5 percent of total health care costs, drugs have been responsible for dramatic improvements in the health status of the public in this country. If we had the same diseases and mortality rates in recent years that we had at the turn of the century, we would have foregone billions of dollars annually due to loss of life and loss of work days. Our calculations demonstrate that even if drugs accounted for only 10 percent of the improvement in mortality and morbidity figures, the benefits of drugs definitely exceed the annual expenditures (costs) for drugs. The evidence indicates that it is very cost-beneficial for employers, insurance carriers, and third-party payors to include drug coverage in their insurance package. Drugs are an important factor in reducing the costs in areas such as labor absenteeism as well as the more costly interventions such as hospitalization and surgery.

UR - http://www.scopus.com/inward/record.url?scp=84907036521&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84907036521&partnerID=8YFLogxK

U2 - 10.3109/10601338509051049

DO - 10.3109/10601338509051049

M3 - Article

AN - SCOPUS:84907036521

VL - 3

SP - 53

EP - 69

JO - Clinical Research Practices and Drug Regulatory Affairs

JF - Clinical Research Practices and Drug Regulatory Affairs

SN - 1060-1333

IS - 1

ER -